Identification of tetracycline combinations as EphB1 tyrosine kinase inhibitors for treatment of neuropathic pain.
Ahmed, M.S., Wang, P., Nguyen, N.U.N., Nakada, Y., Menendez-Montes, I., Ismail, M., Bachoo, R., Henkemeyer, M., Sadek, H.A., Kandil, E.S.(2021) Proc Natl Acad Sci U S A 118
- PubMed: 33627480 
- DOI: 10.1073/pnas.2016265118
- Primary Citation of Related Structures:  
6UMW, 7KPL, 7KPM - PubMed Abstract: 
Previous studies have demonstrated that the synaptic EphB1 receptor tyrosine kinase is a major mediator of neuropathic pain, suggesting that targeting the activity of this receptor might be a viable therapeutic option. Therefore, we set out to determine if any FDA-approved drugs can act as inhibitors of the EphB1 intracellular catalytic domain ...